TrkA-IN-4

• CAT Number: I042382
• CAS Number: 3026111-74-7
• Molecular Formula: C27H21F3N4O5
• Molecular Weight: 538.47
• Purity: ≥95%
• Synonyms: acetyloxymethyl 5-[[3-(1-methylpyrazol-3-yl)-4-(trifluoromethyl)benzoyl]amino]-6-phenylpyridine-3-carboxylate
• InChI: InChI=1S/C27H21F3N4O5/c1-16(35)38-15-39-26(37)19-13-23(24(31-14-19)17-6-4-3-5-7-17)32-25(36)18-8-9-21(27(28,29)30)20(12-18)22-10-11-34(2)33-22/h3-14H,15H2,1-2H3,(H,32,36)
• InChIKey: FMICUWJKVYFTRQ-UHFFFAOYSA-N
• SMILES: CC(=O)OCOC(=O)C1=CC(=C(N=C1)C2=CC=CC=C2)NC(=O)C3=CC(=C(C=C3)C(F)(F)F)C4=NN(C=C4)C

TrkA-IN-4 (Cat No.: I042382) is a selective inhibitor of TrkA (tropomyosin receptor kinase A), a high-affinity receptor for nerve growth factor (NGF). By blocking TrkA activation, TrkA-IN-4 disrupts NGF-mediated signaling pathways involved in pain perception, neuronal survival, and tumorigenesis. It exhibits potent kinase inhibition with minimal off-target effects, making it a valuable tool in neurobiology and cancer research. TrkA-IN-4 is particularly useful for exploring therapeutic strategies aimed at treating chronic pain, neurodegenerative disorders, and cancers with aberrant TrkA signaling.

Reference

[1]. Tang S, et, al. Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo. Eur J Med Chem. 2023 Jan 5;245(Pt 2):114901.
[Content Brief]